Drug Trial Radar · NCT07393373
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
135
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
May 31, 2036
Study completion May 31, 2036
Sponsor
- Lead sponsor
- QED Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially additional participants who completed ACCEL. Participants rolling over directly from the observational ACCEL study must have had at least a 6-month period of growth assessment in that study.
Conditions
- Hypochondroplasia
Interventions
InfigratinibDrug
Infigratinib to be administered by mouth and initiated at the last dose level received in the ACCEL 2/3 study or at the dose selected to be further evaluated after proof-of-concept is established for Phase 2 portion of ACCEL 2/3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (TEAE) and serious TEAETime frame: 10 years
- Changes over time in standing height Z-score in relation to HCH and non-HCH growth chartsTime frame: 10 years
Locations
24 sites in 10 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital
Oakland, California
Childrens Hospital Colorado
Aurora, Colorado
Children's National Hospital
Washington D.C., District of Columbia
Johns Hopkins School of Medicine
Baltimore, Maryland
University of Missouri
Columbia, Missouri
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic
Madison, Wisconsin
Murdoch Children's Research Institute - The Royal Children's Hospital Melbourne
Parkville, Victoria, Australia
London Health Sciences Centre - Children's Hospital of Western Ontario
London, Ontario, Canada
Children's Hospital of Eastern Ontario Research Institute
Ottawa, Ontario, Canada
Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada
Hôpital Femme Mère Enfant
Bron, France
Hôpital Universitaire Necker-Enfants Malades
Paris, France
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants
Toulouse, France
Haukeland University Hospital
Bergen, Norway
Paediatric Clinical Research Unit at Oslo University Hospital
Oslo, Norway
Hospital Pediátrico de Coimbra
Coimbra, Portugal
KK Women's and Children's Hospital
Singapore, Singapore
Unidad de Cirugía Artroscopica, Hopsital MIKS
Vitoria-Gasteiz, Spain
Astrid Lindgren Children's Hospital
Solna, Sweden
Manchester University
Manchester, England, United Kingdom
Sheffield Children's Hospital
Sheffield, England, United Kingdom
Glasgow Clinical Research Facility, Queen Elizabeth University Hospital
Glasgow, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.